Therapure Biomanufacturing, a division of Therapure Biopharma Inc., has signed an agreement with VBI Vaccines Inc. for the manufacture of their coronavirus vaccine candidates. Therapure Biomanufacturing is an integrated contract development and manufacturing organization (CDMO) focused on biologic and high value therapeutics that can provide new options for patient care. Therapure will be responsible for the biomanufacturing of the vaccine drug substance as well as the aseptic fill of the drug product at the Therapure facility in Mississauga, Ontario, Canada.
 
“We are delighted to partner with VBI to assist with providing an effective response to the ongoing COVID-19 pandemic through Therapure’s biomanufacturing and aseptic fill finish services for VBI’s innovative COVID-19 vaccine candidates, which utilize their flexible enveloped virus-like particle (eVLP) platform technology,” said Safa’a Al-Rais, chief operating officer, Therapure. “Therapure prides itself on its development, clinical and commercial cGMP manufacturing expertise providing solutions for biologic therapeutics and innovative drug delivery technologies, which make a difference in patients’ lives.”
 
Jeff Baxter, president and chief executive officer, VBI, said, “We look forward to working with Therapure to address the ongoing public health challenge,” said “Therapure’s proven cGMP biomanufacturing capabilities and expertise with aseptic fill finish make them a great partner as we advance our vaccine candidate into and through clinical studies.”